Mirikizumab for UC: Phase 3 Data Now Published in NEJM

Mirikizumab manufacturer Eli Lilly, which funded the study, is hoping the drug will become the first IL-23 inhibitor to be approved in the United States for the treatment of ulcerative colitis (UC).
MDedge News

source https://www.medscape.com/s/viewarticle/994319?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?